Business Description
Acepodia Inc
ISIN : KYG0073G1091
Description
Acepodia Inc is a clinical stage biotechnology company engaged to develop innovative highly effective first-in-class cell therapies by using Antibody-Cell Conjugation platform technology for cancer that are broadly accessible for patients.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 19.07 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -1.11 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 16.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 67.7 | |||||
| 3-Year EPS without NRI Growth Rate | 67 | |||||
| 3-Year FCF Growth Rate | 55.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.09 | |||||
| 9-Day RSI | 43.22 | |||||
| 14-Day RSI | 42.07 | |||||
| 3-1 Month Momentum % | -26.21 | |||||
| 6-1 Month Momentum % | -35.88 | |||||
| 12-1 Month Momentum % | -46.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 60.01 | |||||
| Quick Ratio | 60.01 | |||||
| Cash Ratio | 59.59 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -268.7 | |||||
| Shareholder Yield % | -1.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 99.43 | |||||
| Operating Margin % | -3240.85 | |||||
| Net Margin % | -2246.7 | |||||
| FCF Margin % | -3165.57 | |||||
| ROE % | -5.79 | |||||
| ROA % | -5.47 | |||||
| ROIC % | -109.08 | |||||
| 3-Year ROIIC % | -56.86 | |||||
| ROC (Joel Greenblatt) % | -77.38 | |||||
| ROCE % | -5.21 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 883.33 | |||||
| PB Ratio | 1.6 | |||||
| Price-to-Tangible-Book | 1.57 | |||||
| EV-to-EBIT | -12.79 | |||||
| EV-to-EBITDA | -15.24 | |||||
| EV-to-Revenue | 269.4 | |||||
| EV-to-FCF | -8.51 | |||||
| Price-to-Net-Current-Asset-Value | 1.72 | |||||
| Price-to-Net-Cash | 1.74 | |||||
| Earnings Yield (Greenblatt) % | -7.82 | |||||
| FCF Yield % | -5.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Acepodia Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil NT$) | 16.904 | ||
| EPS (TTM) (NT$) | -0.67 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 23.78 | ||
| 14-Day RSI | 42.07 | ||
| 14-Day ATR (NT$) | 0.662161 | ||
| 20-Day SMA (NT$) | 18.1725 | ||
| 12-1 Month Momentum % | -46.59 | ||
| 52-Week Range (NT$) | 17 - 35 | ||
| Shares Outstanding (Mil) | 569.64 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Acepodia Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Acepodia Inc Stock Events
| Event | Date | Price (NT$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Acepodia Inc Frequently Asked Questions
What is Acepodia Inc(ROCO:6976)'s stock price today?
The current price of ROCO:6976 is NT$18.10. The 52 week high of ROCO:6976 is NT$35.00 and 52 week low is NT$17.00.
When is next earnings date of Acepodia Inc(ROCO:6976)?
The next earnings date of Acepodia Inc(ROCO:6976) is .
Does Acepodia Inc(ROCO:6976) pay dividends? If so, how much?
Acepodia Inc(ROCO:6976) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers